Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection

Journal of Experimental Medicine

Volumn 185, Issue 7, 1997, Pages 1173-1183

  Martin, Denis ^a   Cadieux, Nathalie ^a   Hamel, Josée ^a   Brodeur, Bernard R ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL MENINGITIS; BACTERICIDAL ACTIVITY; EXPERIMENTAL MODEL; EXPRESSION VECTOR; MOLECULAR CLONING; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; BASE SEQUENCE; CLONING, MOLECULAR; CONSERVED SEQUENCE; GENES, BACTERIAL; IMMUNIZATION, PASSIVE; MENINGOCOCCAL INFECTIONS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEISSERIA MENINGITIDIS; RECOMBINANT PROTEINS; SEQUENCE ANALYSIS, DNA; VACCINATION;

EID: 0030951492     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.185.7.1173     Document Type: Article

References (67)

1. Peltola, H. 1983. Meningococcal disease: still with us. Rev. Infect. Dis. 5:71-91.
2. Schwartz, B., P.S. Moore, and C.V. Broome. 1989. Global epidemiology of meningococcal disease. Clin. Microbiol. Rev. 2(Suppl.):S118-S124.
3. Whittle, H.C., and B.M. Greenwood. 1976. Meningococcal meningitis in the northern savanna of Africa. Trop. Doct. 6: 99-104.
4. Frasch, C.E., W.D. Zollinger, and J.T. Poolman. 1988. Sero-type antigens of Neisseria meningitidis and a proposal scheme for designation of serotypes. Rev. Infect. Dis. 7:504-510.
5. Frasch, C.E. 1989. Vaccines for prevention of meningococcal disease. Clin. Microbiol. Rev. 2(Suppl.):S134-S138.
6. Frasch, C.E. 1995. Meningococcal vaccines: past, present and future. In Meningococcal Disease. K. Cartwright, editor. John Wiley & Sons Ltd, New York, NY. 245-283.
7. Artenstein, M.S., R. Gold, J.G. Zimmerly, F.A. Wyle, H. Schneider, and C. Harkins. 1970. Prevention of meningococcal disease by group C polysaccharide vaccine. N. Engl. J. Med. 282:417-420.
8. Peltola, H., P.H. Mäkelä, H. Käyhty, H. Jousimies, E. Hera, K. Hällström, A. Sivonen, O.-V. Renkonen, O. Pettay, V. Karanko et al. 1977. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N. Engl. J. Med. 297:686-691.
9. Reingold, A.L., C.V. Broome, A.W. Hightower, G.W. Ajello, G.A. Bolan, C. Adamsbaum, E.E. Jones, C. Phillips, H. Tiendrebeogo, and A. Yada. 1985. Age specific difference in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet. 2:114-118.
10. Poolman, J.T. 1995. Development of a meningococcal vaccine. Infect. Agents Dis. 4:13-28.
11. Lepow, M.L., I. Goldschneider, R. Gold, M. Randolph, and E.C. Gotschlich. 1977. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics. 60:673-680.
12. Costantino, P., S. Viti, A. Podda, M.A. Velmonte, L. Nencioni, and R. Rappuoli. 1992. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine. 10:691-698.
13. Jennings, H.J., and C. Lugowski. 1981. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J. Immunol. 127:1011-1018.
14. Beuvery, E.G., F. Miedema, R. van Delft, and K. Haverkamp. 1983. Preparation and immunochemical characterization of meningococcal serogroup C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines. Infect. Immun. 40:39-45.
15. Beuvery, E.C., A. Kaaden, V. Kanhai, and A.B. Leussink. 1983. Physiochemical and immunochemical characterization of meningococcal serogroup A polysaccharide-tetanus toxoid conjugates prepared by two methods. Vaccine. 1:31-36.
16. Anderson, E.L., T. Bowers, C.M. Mink, D.J. Kennedy, R.B. Belshe, H. Harakeh, L. Pais, P. Holder, and G.M. Carlone. 1994. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect. Immun. 62: 3391-3395.
17. Zollinger, W.D., and E. Moran. 1991. Meningococcal vaccines - present and future. Trans. Roy. Soc. Trop. Med. Hyg. 85(Suppl.):37-43.
18. Mandrell, R.E., and W.D. Zollinger. 1982. Measurement of antibodies to meningococcal serogroup B polysaccharide: Low avidity binding and equilibrium binding constants. J. Immunol. 129:2172-2177.
19. Zollinger, W.D., and R.E. Mandrell. 1983. Importance of complement source in bactericidal activity ot human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 40:257-264.
20. Goldschneider, I., E.C. Gotschlich, and M.S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of antibodies. J. Exp. Med. 129:1307-1326.
21. Goldschneider, I., E.C. Gotschlich, and M.S. Artenstein. 1969. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 129:1327-1378.
22. Gotschlich, E.C., I. Goldschneider, and M.S. Artenstein. 1969. Human immunity to the meningococcus. IV. Immunogenicity of serogroup A and serogroup C polysaccharides inhuman volunteers. J. Exp. Med. 129:1367-1384.
23. Frasch, C.E., and S.S. Chapman. 1973. Classification of Neisseria meningitidis serogroup b into distinct serotypes. III. Application of a new bactericidal inhibition technique to distribution of serotypes among cases and carriers. J. Infect. Dis. 127:149-154.
24. Jones, D.M., and J. Eldridge. 1979. Development of antibodies to meningococcal protein and lipopolysaccharide antigens in healthy carriers. J. Med. Microbiol. 12:107-111.
25. Saukkonen, K., H. Abdillahi, J.T. Poolman, and M. Leinonen. 1987. Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development. Microb. Pathog. 3:261-267.
26. Saukkonen, K., M. Leinonen, H. Abdillahi, and J.T. Poolman. 1989. Comparative evaluation of potential components for group B nieningococcal vaccine by passive protection in the infant rat model and in vitro bactericidal assay. Vaccine. 7: 325-328.
27. Frasch, C.E., C.-M. Tsai, and L.F. Mocca. 1986. Outer membrane proteins of Neisseria meningitidis'. structure and importance in meningococcal disease. Clin. Invest. Med. 9:101-107.
28. Brodeur, B.R., Y. Larose, P. Tsang, J. Hamel, F. Ashton, and A. Ryan. 1985. Protection against infection with Neisseria meningitidis group B serotype 2b by passive immunization with serotype-specific monoclonal antibody. Infect. Immun. 50:510-516.
29. Høiby, E.A., E.A. Rosenqvist, L.O. Frøholm, G. Bjune, B. Feiring, H. Nøkleby, and E. Rønnild. 1991. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH (Natl. Inst. Public Health) Ann. (OSLO). 14:147-56.
30. Zollinger, W.D., J. Boslego, E. Moran, J. Garcia, C. Cruz, S. Ruiz, B. Brandt, M. Martinez, J. Arther, P. Underwood et al. 1991. Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile. NIPH (Natl. Inst. Public Health) Ann. (OSLO). 14:211-213.
31. van der Ley, P.A., J.E. Heckels, M. Virji, P. Hoogerhout, and J.T. Poolman. 1991. Topology of outer membrane porins in pathogenic Neisseria spp. Infect. Immun. 59:2963-2971.
32. Olyhoek, A.J.M., J. Sarkari, M. Bopp, G. Morelli, and M. Achtman. 1991. Cloning and expression in Escherichia coli of Opc, the gene for an unusual class 5 outer membrane protein from Neisseria meningitidis. Microbiol. Pathog. 11:249-257.
33. Rosenqvist, E., E.A. Høiby, E. Wedege, B. Kusecek, and M. Achtman. 1993. The 5c protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J. Infect. Dis. 167:1065-1073.
34. van der Ley, P.A., J. van der Biezen, C.C.A.M. Peeters, and J.T. Poolman. 1993. Use of transformation to construct antigenic hybrids of the class 1 outer membrane protein in Neisseria meningitidis. Infect. Immun. 61:4724-4733.
35. van der Ley, P.A., J. van der Biezen, and J.T. Poolman. 1995. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine. 13:401-407.
36. van der Ley, P.A, and J.T. Poolman. 1992. Construction of multivalent class 1 OMP expressing meningococcal vaccine strain. Infect. Immun. 60:3156-3161.
37. Danve, B., L. Lissolo, M. Mignon, P. Dumas, P.P. Colombani, S. Colombani, A.B. Schryvers, and M.-J. Quentin-Millet. 1993. Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine. 11:1214-1220.
38. Pettersson, A., A.J. Kuipers, M. Pelzer, E.P.M. Verhagen, R.H. Tiesjema, J. Tommassen, and J.T. Poolman. 1990. Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria menigitidis are bactericidal and strains-specific. Infect.l immun. 58:3036-30141.
39. Bhatnagar, N.B., and C.E. Frasch. 1990. Expression of Neisseria meningitidis iron-regulated outer membrane proteins including a 70-Kilodalton transferrin receptor, and their potential for use as vaccines. Infect. Immun. 58:2875-2881.
40. Ala'Aldeen, D.A., and S.P. Borriello. 1996. The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains. Vaccine. 14:49-53.
41. Cannon, J.G., W.J. Black, I. Nachamkin, and P.W. Stewart. 1984. Monoclonal antibody that recognizes an outer membrane antigen common to the pathogenic Neisseria species. Infect. Immun. 43:994-999.
42. Bhattacharjee, A.K., E.E. Moran, and W.D. Zollinger. 1990. Antibodies to meningococcal H.8 (Lip) antigen fail to show bactericidal activity. Can. J. Microbiol. 36:117-122.
43. Munkley, A., C.R. Tinsley, M. Virji, and J.E. Heckels. 1991. Blocking of bactericidal killing of Neisseria meningitidis by antibodies directed against class 4 outer membrane proteins. Microbiol. Pathol. 11:447-452.
44. Yanisch-Perron, C., J. Viera, and J. Messing. 1985. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene (Amst.). 33:103-119.
45. Sambrook, J., E.F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Plainview, NY. 12.21-12.23.
46. Studier, F. W., A.H. Rosenberg, J.J. Dunn, and J.W. Dubendorff. 1990. Use of T7 RNA polymerase to direct expression of cloned genes. In Methods Enzymol. J.N. Abelson and M.I. Simon, editors. Academic Press, Inc., San Diego, CA. 185: 60-89.
47. Wang, R.F., and S.R. Kushner. 1991. Construction of versatile low-copy-number vectors for cloning, sequencing and gene expression in Escherichia coli. Gene (Amst.). 100:195-199.
48. Lowry, O.H., N.J. Rosenbrough, A.L. Farr, and R.J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
49. Hamel, J., B.R. Brodeur, Y. Larose, P.S. Tsang, A. Belmaaza, and S. Montplaisir. 1987. A monoclonal antibody directed against a serotype-specific, outer-membrane protein of Haemophilus influenzae type b. J. Med. Microbiol. 23:163-170.
50. Lussier, M., B.R. Brodeur, and S. Winston. 1989. Detection of Neisseria gonorrhoeae by dot enzyme immunoassay using monoclonal antibodies. J. Immunoassay. 10:373-394.
51. Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.). 227:680-685.
52. Martin, D., Y. Larose, J. Hamel, J. Lagacé, and B.R. Brodeur. 1988. Heterohybridomas secreting human monoclonal antibodies against Haemophilus influenzae type b. Eur. J. Immunal. 18:601-606.
53. Tsai, C.-M., and C.E. Frasch. 1982. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Annal. Biochem. 119:115-119.
54. Matsudaira, P. 1987. Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J. Biol. Chem. 262:10035-10038.
55. Martin, D., M.S. Peppler, and B.R. Brodeur. 1992. Immunological characterization of the lipooligosaccharide B band of Bordetella pertussis. Infect. Immun. 60:2718-2725.
56. Martin, D., N. Cadieux, J. Hamel, and B.R. Brodeur. 1996. Identification of a highly conserved outer membrane protein of Neisseria meningitidis. Am. Soc. Microbiol. 187(Abstr.):187.
57. Michaelis, S., and J. Beckwith. 1982. Mechanism of incorporation of cell envelope proteins in Escherichia coli. Ann. Rev. Microbiol. 36:435-465.
58. Virji, M., K. Makepeace, D.J.P. Ferguson, M. Achtman, and E.R. Moxon. 1993. Meningococcal Opa and Opc proteins: their role in colonization and invasion of human epithelial and endothelial cells. Mol. Microbiol. 10:499-510.
59. Aho, E.L., J.A. Dempsey, M.M. Hobbs, D.G. Klapper, and J.G. Cannon. 1991. Characterization of the opa (class 5) gene family of Neisseria meningitidis. Mol. Microbiol. 5:1429-1437.
60. Hobbs, M.M., A. Seiler, M. Achtman, and J.G. Cannon. 1994. Microevolution within a clonal population of pathogenic bacteria: recombination, gene duplication and horizontal genetic exchange in the opa gene family of Neisseria meningitidis. Mol. Microbiol. 12:171-180.
61. Ross, S.C., P.J. Rosenthal, H.M. Berberic, and P. Densen. 1987. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement deficient individuals. J. Infect. Dis. 155:1266-1275.
62. Densen, P. 1989. Interaction of complement with Neisseria meningitidis and Neisseria gonorrhoeae. Clin. Microbiol. Rev. 2(Suppl.): S11-S17.
63. Martin, D., R. Munson, Jr., S. Grass, P. Chong, J. Hamel, G. Zobrist, M. Klein, and B.R. Brodeur. 1991. Mapping of B-cell epitopes on the outer membrane P2 porin protein of Haemophilus influenzae by using recombinant proteins and synthetic peptides. Infect. Immun. 59:1457-1464.
64. McGuinness, B.T., P.R. Lambden, and J.E. Heckels. 1993. Class 1 outer membrane protein of Neisseria meningitidis: epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology. Mol. Microbiol. 7:505-514.
65. Fernandez de Cossio, M.E., M. Ohlin, M. Llano, B. Selander, S. Cruz, J. Del Valle, and C.A. Borrebaeck. 1992. Human monoclonal antibodies against an epitope on the class 5c outer membrane protein common to many pathogenic strains of Neisseria meningitidis.J. Infect. Dis. 166:1322-1328.
66. Verheul, A.F., A.J. Kuipers, A.K. Braat, H.A. Dekker, C.C. Peeters, H. Snippe, and J.T. Poolman. 1994. Development, characterization, and biological properties of meningococcal immunotype L3,7,(8),9-specific monoclonal antibodies. Clin. Diagn. Lab. Immunol. 1:729-736.
67. Idänpään-Heikküä, I., S. Muttilainen, E. Wahlström, L. Saarinen, M. Leinonen, M. Sarvas, and P.H. Mäkelä. 1995. The antibody response to a prototype liposome vaccine containing Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis. Vaccine. 13:1501-1508.